Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00030173
Status:
COMPLETED
Last Update Posted:
2009-01-08
First Post:
2002-02-07
Brief Title:
A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 1 Dose Escalation Trial to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Epothilone D in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization Since microtubules are essential for mitosis motility secretion and proliferation the observed antitumor effects of epothilones have been attributed to their ability to initiate cell death by inhibiting such processes Epothilone D has demonstrated in vitro cytotoxic activity in a panel of human cell lines equipotent to that of paclitaxel In vivo Epothilone D has also shown significant antitumor activity in a range of xenograft models including paclitaxel-resistant xenografts Epothilone D is more potent than paclitaxel in cell lines that demonstrate multiple drug resistant activity overexpressing p-glycoprotein
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None